PRSS54

Across TCGA pan-cancer cohorts, PRSS54 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRSS54 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRSS54 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRSS54 expression acts as an unfavorable survival marker.

OV, READ, and LIHC are the cancer types where PRSS54 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
READ	OS	Median	II,III,IV	0.527	0.933	<.001	15	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRSS54–OV (DFS)

Open the OV breakdown →